Type 3 VWD

Prev
 1 / 20 
Next
Prev
 1 / 20 
Next

Learning objectives

After completing this quiz, the learner should be able to:

  • interpret type 3 VWD as functional absence of VWF rather than simply “very low VWF”
  • explain why type 3 VWD produces both mucocutaneous bleeding and hemophilia-like joint and muscle bleeding
  • distinguish type 3 VWD from severe type 1 VWD using laboratory findings, inheritance, and clinical implications
  • apply the rationale for VWF replacement therapy when endogenous VWF is absent
  • identify when long-term prophylaxis should be considered in patients with severe and recurrent bleeding
  • recognize clinical clues suggesting anti-VWF alloantibodies and understand why they alter management
  • integrate laboratory results, bleeding phenotype, and treatment principles to guide management of patients with type 3 VWD

A child has undetectable VWF antigen, undetectable VWF platelet-dependent activity, absent multimers, and FVIII 4 IU/dL. Which diagnosis best fits this pattern?

a
Type 1 VWD
Type 1 VWD is a partial quantitative deficiency. VWF is reduced, but not virtually absent, and multimers are usually present.
b
Type 2A VWD
Type 2A VWD is a qualitative disorder with loss of high-molecular-weight multimers, but VWF antigen and activity are not typically absent.
c
Type 2N VWD
Type 2N VWD causes disproportionately low FVIII because VWF cannot bind FVIII normally, but VWF antigen and multimers are usually present.
d
Type 3 VWD
This pattern is classic for type 3 VWD: VWF antigen and activity are absent or virtually absent, multimers are absent, and FVIII is markedly reduced because VWF is not available to stabilize it.

Why is FVIII often markedly reduced in type 3 VWD?

a
The F8 gene is usually deleted
The primary genetic defect in type 3 VWD is usually in VWF, not F8.
b
VWF is absent and cannot stabilize FVIII
FVIII circulates bound to VWF. When VWF is absent, FVIII is not protected from premature clearance, so FVIII activity may fall into a hemophilia-like range.
c
Platelets consume FVIII
Platelet consumption is not the mechanism of low FVIII in type 3 VWD.
d
FVIII cannot bind collagen
Collagen binding is a VWF function, not the explanation for FVIII survival in plasma.

Which bleeding pattern is most characteristic of type 3 VWD compared with milder VWD?

a
Only mild bruising after trauma
b
Isolated prolonged bleeding time without clinical bleeding
Type 3 VWD is clinically significant; it is not defined by an isolated screening-test abnormality without bleeding.
c
Severe mucocutaneous bleeding plus possible joint and muscle bleeding
Type 3 VWD can cause both mucocutaneous bleeding from absent VWF-mediated platelet adhesion and deeper bleeding from markedly reduced FVIII.
d
Only thrombosis after surgery
Type 3 VWD is a bleeding disorder. Thrombotic considerations may arise during replacement therapy, but thrombosis is not the defining phenotype.

Why is desmopressin not useful in type 3 VWD?

a
It destroys infused VWF
Desmopressin does not destroy infused VWF.
b
It only works in platelet-type VWD
Desmopressin may be useful in selected type 1 and some type 2 patients, but type 3 lacks the releasable VWF reserve needed for response.
c
There is little or no endogenous VWF reserve to release
Desmopressin works by releasing stored endogenous VWF. In type 3 VWD, there is little or no VWF reserve, so release therapy cannot correct the defect.
d
It lowers FVIII in all patients
Desmopressin usually raises FVIII in responsive patients because released VWF stabilizes FVIII; the problem in type 3 is lack of releasable VWF.

Which statement best distinguishes type 3 VWD from severe type 1 VWD?

a
Type 3 VWD is qualitative, while severe type 1 is quantitative
Both type 1 and type 3 VWD are quantitative categories. The distinction is partial deficiency versus virtual absence.
b
Type 3 VWD reflects absent or virtually absent VWF and is usually recessive
Type 3 VWD reflects functional absence of VWF and is typically recessive, often with biallelic severe VWF variants. That distinction matters for phenotype, counseling, replacement needs, and alloantibody risk.
c
Severe type 1 VWD always has normal FVIII
FVIII may be reduced in severe type 1 VWD because VWF stabilizes FVIII.
d
Type 3 VWD has normal multimers
Multimers are absent or nearly absent in type 3 VWD because VWF itself is absent or nearly absent.

A patient with type 3 VWD is undergoing major surgery. Which treatment principle is most appropriate?

a
Replace VWF and monitor both VWF activity and FVIII activity
Major surgery in type 3 VWD requires replacement of the missing VWF platform, with monitoring of both VWF activity and FVIII activity because both platelet-dependent hemostasis and FVIII stabilization are affected.
b
Target FVIII alone because VWF only affects platelets
FVIII alone does not restore VWF-mediated platelet adhesion.
c
Use desmopressin as primary therapy
Desmopressin is ineffective because there is little or no endogenous VWF to release.
d
Avoid all antifibrinolytic therapy in mucosal procedures
Antifibrinolytics can be useful adjuncts for mucosal bleeding, though they do not replace the need for VWF when VWF replacement is indicated.

Why can repeated dosing with some plasma-derived VWF/FVIII concentrates require monitoring of FVIII?

a
FVIII may accumulate
Some plasma-derived VWF/FVIII concentrates contain FVIII. With repeated dosing, especially during surgery or intensive replacement, FVIII may accumulate and should be monitored.
b
FVIII is always absent after VWF infusion
FVIII usually rises after VWF replacement because infused VWF stabilizes endogenous FVIII, and some products also contain FVIII.
c
FVIII causes VWF alloantibodies
Anti-VWF alloantibodies are directed against VWF and are related especially to severe/null VWF genotypes, not simply to FVIII exposure.
d
FVIII prevents VWF from binding platelets
FVIII does not prevent VWF from binding platelets.

When should long-term prophylaxis be considered in type 3 VWD?

a
Any patient with one mild bruise
Trivial bleeding alone does not justify long-term prophylaxis.
b
Only patients with normal FVIII
Low FVIII is common in type 3 VWD and may contribute to the need for replacement-based prophylaxis.
c
Only patients who respond to desmopressin
Desmopressin response is not the basis for prophylaxis in type 3 VWD because desmopressin is not effective when VWF is absent.
d
Selected patients with severe and frequent bleeding
Long-term prophylaxis may be considered for selected patients with severe and frequent bleeding, such as recurrent joint, muscle, GI, or severe mucosal bleeding, with periodic reassessment.

Which scenario should raise concern for anti-VWF alloantibodies in type 3 VWD?

a
Excellent recovery after every VWF infusion
Excellent recovery after VWF infusion argues against clinically important anti-VWF alloantibodies.
b
Poor VWF recovery, ongoing bleeding, and anaphylaxis after VWF concentrate
Poor recovery after VWF infusion, persistent bleeding despite apparently appropriate dosing, infusion reactions, or anaphylaxis should raise concern for anti-VWF alloantibodies.
c
Mild bruising with normal VWF levels
Normal VWF levels do not fit type 3 VWD.
d
Isolated low ferritin after heavy menses
Iron deficiency may reflect bleeding burden, especially heavy menstrual bleeding, but it does not specifically suggest anti-VWF alloantibodies.

Why does type 3 VWD require planned replacement around delivery?

a
VWF always becomes supranormal during pregnancy in type 3 VWD
Pregnancy may raise many hemostatic factors, but type 3 VWD does not reliably correct VWF absence.
b
Type 3 VWD usually does not normalize VWF during pregnancy because endogenous VWF is absent
Type 3 VWD generally lacks endogenous VWF reserve, so pregnancy does not reliably normalize VWF. Delivery and postpartum hemostasis usually require planned VWF replacement support.
c
FVIII replacement alone corrects all delivery risk
FVIII alone does not restore VWF-mediated platelet adhesion.
d
Postpartum bleeding does not occur in type 3 VWD
Postpartum bleeding risk can be significant in type 3 VWD.

A patient with type 3 VWD has recurrent ankle hemarthroses and early arthropathy. What is the best explanation?

a
Very low FVIII can produce hemophilia-like joint bleeding
Absent VWF leads to reduced FVIII survival. When FVIII is very low, patients with type 3 VWD may develop hemophilia-like joint or muscle bleeding.
b
Type 3 VWD always causes platelet thrombosis
Type 3 VWD is a bleeding disorder, not a platelet thrombosis disorder.
c
VWF replacement causes joint bleeding
VWF replacement is used to prevent or treat bleeding, not to cause hemarthroses.
d
Joint bleeding excludes VWD
Joint bleeding does not exclude VWD; it can occur in severe VWD, especially type 3.

Which statement best captures the central reasoning lesson of type 3 VWD?

a
Type 3 VWD is just type 1 VWD with a lower number
Type 3 VWD is not simply the far end of type 1. It differs in inheritance, phenotype, treatment dependence, and alloantibody risk.
b
Type 3 VWD reveals what happens when the VWF platform is absent
Type 3 VWD reveals the full biology of VWF. When VWF is absent, both platelet adhesion and FVIII stabilization fail.
c
Type 3 VWD is mainly a platelet-count disorder
Platelet count is not the defining abnormality in type 3 VWD.
d
Type 3 VWD is diagnosed by FVIII level alone
FVIII is low secondarily. The diagnosis rests on absent or virtually absent VWF antigen, activity, and multimers.

Sort each item into the category it most directly supports in type 3 VWD reasoning.

recurrent hemarthroses prompting prophylaxis consideration
bsent VWF multimers
desmopressin is ineffective
VWF replacement is needed for major surgery
undetectable VWF antigen and activity
anaphylaxis after VWF-containing concentrate
Diagnosis of type 3 VWD
Treatment implication
Complication or special concern

Match the finding with its best interpretation.

FVIII 4 IU/dL in type 3 VWD
poor recovery after VWF infusion
no response to desmopressin
consider anti-VWF alloantibodies
absent VWF cannot stabilize FVIII
little or no endogenous VWF is available to release
Correct! Sorry, Incorrect.

Closing Note

Type 3 VWD is not just the absence of a laboratory value. It is the absence of VWF as a hemostatic platform. When VWF is absent, platelet adhesion and FVIII survival both fail.

Prev
 1 / 20 
Next